The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo
Open accessAbstract
Background Attention-deficit/hyperactivity disorder is a psychiatric disorder that starts in childhood. The mechanism of action of methylphenidate, the most common treatment for attention deficit hyperactivity disorder, is unclear. In vitro, the affinity of methylphenidate for the norepinephrine transporter (NET) is higher than that for the dopamine transporter (DAT). The goal of this study was to use positron emission tomography to measure the occupancy of brain norepinephrine transporter by methylphenidate in vivo in humans. Methods We used (S,S)-[¹¹C] methylreboxetine ([¹¹C]MRB) to determine the effective dose 50 (ED₅₀) of methylphenidate for NET. In a within-subject design, healthy subjects (n = 11) received oral, single-blind placebo and 2.5, 10, and 40 mg of methylphenidate 75 min before [¹¹C]MRB injection. Dynamic positron emission tomography imaging was performed for 2 hours with the High Resolution Research Tomograph. The multilinear reference tissue model with occipital cortex as the reference region was used to estimate binding potential non-displaceable (BP(ND)) in the thalamus and other NET-rich regions. Results BP(ND) was reduced by methylphenidate in a dose-dependent manner in thalamus and other NET-rich regions. The global ED₅₀ was estimated to be .14 mg/kg; therefore, the average clinical maintenance dose of methylphenidate (.35-.55 mg/kg) produces 70% to 80% occupancy of NET. Conclusions For the first time in humans, we demonstrate that oral methylphenidate significantly occupies NET at clinically relevant doses. The ED₅₀ is lower than that for DAT (.25 mg/kg), suggesting the potential relevance of NET inhibition in the therapeutic effects of methylphenidate in attention-deficit/hyperactivity disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in other regions, such as frontal lobes, methylphenidate blocks 70% to 80% of norepinephrine transporters (15), which reuptake both dopamine and norepinephrine, leading to increased extracellular catecholamine levels (15).”
From Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis (2014) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The increase of IFG/insula activation with methylphenidate is likely mediated by both noradrenergic and dopaminergic mechanisms, given that in frontal regions both in humans 15, 69, 70 and in animals 69, 70 methylphenidate increases noradrenaline equally or more than dopamine via reuptake inhibition of noradrenaline transporters, which clear both catecholamines.”
From Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis (2014) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NE systems have been implicated as key targets for MPH, with MPH dose-dependently blocking the NET in the thalamus and other NET-rich regions; the estimated occupancy of the NET at therapeutic doses of 0.35 to 0.55 mg/kg MPH is 70% to 80% (168).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationExpression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991) · Nature · doi:10.1038/350350a0 · Cited by 933
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationThe neural correlates of attention deficit hyperactivity disorder: an ALE meta‐analysis
Dickstein, S. G., Bannon, K., Xavier Castellanos, F., & Milham, M. P. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01671.x · Cited by 745
Morón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Ichise, M., Liow, J., Lu, J., Takano, A., Modell, K. J., Toyama, H., Suhara, T., Suzuki, K., Innis, R. B., & Carson, R. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000085441.37552.ca · Cited by 651
Self-citationBerridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617
Cited by
Sorted by citations
Items 201–236 of 236
Oya, M., Matsuoka, K., Kubota, M., Kitamura, S., Kataoka, Y., Kokubo, N., Takahata, K., Seki, C., Endo, H., Tagai, K., et al. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13911 · Cited by 1
Mondragón, J. D., Marcolini, S., Giacobbo, B. L., Elsinga, P. H., Dierckx, R., Tollenaere, M., Dam, D. V., & Deyn, P. P. D. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109581 · Cited by 1
García‐Olivares, J., Yegla, B., Koch, J., Yu, C., & Rubin, J. S. (2026) · Drugs in R&D · doi:10.1007/s40268-026-00543-y · Cited by 1
van der Pal, Z., Reneman, L., Mutsaerts, H. J., Kaiser, A., Bottelier, M., Geurts, H., & Schrantee, A. (2025) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111545
Stormezand, G. N. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_31 · Cited by 1
Behavioral Medical Epigenetics
Cox, O., & Lee, R. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00008-9 · Cited by 3
Proper administration of psychostimulants
Nam, B. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.8.502 · Cited by 1
Schmitz, F., Ferreira, F. S., Silveira, J. S., Júnior, O. V. R., & Wyse, Â. T. D. S. (2022) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2022.107637 · Cited by 1
Cognitive and electrophysiological responses to dopaminergic manipulations
Linssen, A. M. W. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20130118al · Cited by 1
Neural substrates of amphetamine induced impulsive behaviour
Twiston-Davies, F. L. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Villemonteix, T. (2015) · theses.fr (ABES) · doi:10.70675/84304c2az6a4fz488czbda7z8935968796d4 · Cited by 1
Williams, Y. S. (2011) · UKnowledge (University of Kentucky)
The alpha2C-adrenoceptor as a neuropsychiatric drug tar-get - PET studies in human subjects
Lehto, J. (2015) · UTUPub (University of Turku)
The role of central catecholamines in performance during prolonged exercise in warm conditions
Cordery, P. (2013) · Loughborough University Research Repository (Loughborough University)
Plant, C. P. (2016) · CSUSB ScholarWorks (California State University, San Bernardino)
Dreyer, J. (2015) · Boloka Institutional Repository (North-west University)
Thurston, L. T. (2016) · QSpace (Queen's University Library)
Ellenbroek, B. A., & Youn, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801657-2.00008-2
Behavioral medical epigenetics
Cox, O., & Lee, R. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00017-7
(2013) · مجلة دراسات الطفولة · doi:10.21608/jsc.2013.93222
Guilé, J.-M. (2012) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(12)53147-0
Managing Sedation, Orthostasis and Tachycardia
Meyer, J. M., & Stahl, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108553575.010
Walitza, S., Smigielski, L., & Gerlach, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_8 · Cited by 2
Smart drugs among students – multidimensional view on present ways of cognitive enhancement
Pisera, P., Kiełkowicz, A., Pactwa, F., Popińska, Z., Żmuda, B., Ślusarczyk, D., Jakubowska, W., & Żuberek, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.49.01.007
Neurobiology of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Radonjić, N. V. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_33 · Cited by 2
Harrington, K. (2024) · The Conversation · doi:10.64628/aai.3a6ae94dg
Therapeutic Effect of LEV in a Propionic Acid‐Induced Autism Model via AMPK/SIRT1 Pathway
MECİT, T., Altuntaş, İ., Erdoğan, M. A., Uyanıkgil, Y., & Erbaş, O. (2025) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.70055
van der Pal, Z., Reneman, L., Geurts, H. M., Boucherie, D. E., Douw, L., & Schrantee, A. (2025) · medRxiv · doi:10.1101/2025.11.26.25341066
Ding, Y., Pirraglia, E., Wang, J., Mikheev, A., Chen, J., Rusinek, H., & Babb, J. S. (2026) · Diagnostics · doi:10.3390/diagnostics16020190
Self-citationXing, L., Yujie, C. H. E. N., Chengguo, M. I. A. O., & Yang, Z. (2026) · Advances in Psychological Science · doi:10.3724/sp.j.1042.2026.0313
Dafny, N., Reyes-Vasquez, C., & Claussen, C. M. (2026) · Journal of Experimental Neurology · doi:10.33696/neurol.7.124
Ruthirakuhan, M. T., Mills, M., Rosenberg, P. B., Haughey, N. J., Mintzer, J. E., Brawman‐Mintzer, O., Craft, S., Herrmann, N., Lerner, A. J., Levey, A. I., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02055-y
Yamashita, M., Shou, Q., Hamatani, S., Matsuzaki, H., Fujieda, M., Hirano, Y., Kagitani-Shimono, K., Okazawa, H., & Mizuno, Y. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03206-z
Cognitive impairment: quantification and possibilities for pharmacological treatment
Housden, C. R. (2013) · Apollo (University of Cambridge) · doi:10.17863/cam.16550
Metadata
- Authors
- Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S.
- Affiliations
- Yale University (US)
- Corresponding author
- Ding, Yu-Shin
- ORCID
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 68
- Issue
- 9
- Pages
- 854-860
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC3742016
- OpenAlex
- W2110412456
- Cited by
- 236
- References
- 41
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 8 · 2020: 12 · 2019: 18 · 2018: 16 · 2017: 19 · 2016: 18 · 2015: 20 · 2014: 20 · 2013: 26 · 2012: 18
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (DA019062, R56DA19062)
- National Center for Research Resources (UL1 RR024139)
- National Institutes of Health, and National Institutes of Health roadmap for Medical Research (K12 DA000167)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, norepinephrine transporter, attention deficit hyperactivity disorder, dose-response relationship, thalamus, binding potential, dopamine transporter, mechanism of action
- MeSH terms
- Reboxetine, Adult, Central Nervous System Stimulants, Brain, Dose-Response Relationship, Drug, Female, Humans, Magnetic Resonance Imaging, Male, Methylphenidate, Morpholines, Radioligand Assay, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
